GlaxoSmithKline finalized a deal to scoop up Human Genome Sciences for $14.25 a share in cash.
The deal values HGS at $3.6 billion on an equity basis, or $3 billion net of cash and debt.
FACEBOOK 
TWITTER
8.60 | 
0.28 |